No Data
Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.
The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.
GTJA: The centralized procurement of Chinese Patent Medicine is still in the early stages, and quality improvement and expansion are expected to continue to progress.
GTJA released a Research Report stating that the bidding for the third batch of national Chinese Patent Medicine centralized procurement has opened, with the reduction slightly exceeding expectations.
ZHONGZHIPHARM (03737.HK) received a Shareholding increase of 0.839 million shares by the Chairman and Executive Director Lai Zhitian.
On January 9, the latest equity disclosure from the Stock Exchange shows that on January 7, 2025, ZHONGZHIPHARM (03737.HK) was increased by Chairman and Executive Director Lai Zhitian in the market at an average price of HKD 1.00 per share, involving about HKD 0.839 million. After the increase, Lai Zhitian's latest shareholding number is 564,087,800 shares, with the shareholding ratio rising from 65.22% to 65.32%.
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
